SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst heightened competitive concerns following Amazon Pharmacy's direct offering of Novo Nordisk's GLP-1 weight loss pill, which many in the community view as a significant headwind. While a vocal bearish contingent cites overvaluation and predicts further downside, a segment of investors sees current price levels as a strong buying opportunity, banking on the company's diversified telehealth platform and international expansion. The market is actively debating HIMS's growth trajectory and valuation as it navigates this evolving competitive landscape.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is experiencing extreme volatility and massive gains, largely fueled by a significant special cash dividend and discussions around a potential pivot to blockchain-based assets. The community is intensely focused on short squeeze potential and the dividend's impact, though many debate the company's underlying fundamentals against the backdrop of its dramatic price movements.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is experiencing significant buzz following a substantial stock and warrant offering to an institutional investor, priced notably above recent trading levels. This move signals strong institutional confidence in the company's future growth, particularly within the burgeoning autonomous drone and defense technology sector. While some debate potential dilution, many in the community are bullish, anticipating major acquisitions and contracts, especially with an investor conference approaching and heightened global defense spending.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with investors expressing a mix of frustration over recent stock performance and renewed optimism for Briumvi's competitive standing. The community is actively discussing a competitor's recent regulatory setback, which highlights Briumvi's favorable profile, while anticipating potential strategic updates from the upcoming J.P. Morgan Healthcare Conference.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amid intense buyout speculation, fueled by strong financial performance and anticipation of critical updates on its AUR200 pipeline, particularly regarding planned Phase 2 indications. Community discussion highlights growing frustration with management's perceived lack of transparency, even as the company's strong fundamentals and recent patent lawsuit consolidation position it as a compelling acquisition target in a dynamic biotech M&A environment.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is currently trending with significant community discussion around its recently announced token burn proposal, aiming for deflationary tokenomics, and a new roadmap. Despite a recent delisting, strong bullish sentiment persists due to its perceived low market cap and continued presence on major exchanges, with many anticipating substantial upside as a liquid staking protocol.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is rallying due to significant regulatory clarity, as the FDA has confirmed a path for sonelokimab's Biologics License Application across key inflammatory skin disease indications without requiring additional pivotal trials. The community views this as a major de-risking event, fueling strong speculation around the drug's "best-in-class" potential, substantial upside, and renewed buyout interest from major pharmaceutical players.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is trending due to significant momentum following its IPO lock-up expiration, which expanded its publicly traded float, alongside news of a private placement and a strategic acquisition. The community is buzzing with high-stakes discussions, drawing parallels to other volatile Hong Kong-based microcap stocks known for explosive, speculative runs and potential short squeezes.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending following its recent strong earnings report, which paradoxically led to a significant price pullback and widespread investor confusion. Community discussion is focused on increased competitive pressures within the observability sector, notably after recent acquisitions by rivals, while also considering rumors about Datadog exploring a potential takeover of GitLab. Despite the volatile price action, many investors view current levels as a compelling long-term buying opportunity, citing the company's robust fundamentals and pivotal role in AI-driven cloud infrastructure.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently trending due to a significant agreement with Meta Platforms to develop a nuclear energy campus in Ohio, aimed at powering future AI data centers. This deal, alongside anticipated DOE support for fuel and recent discussions on nuclear energy, has fueled intense bullish sentiment regarding the future of small modular reactors for AI infrastructure, despite some community concerns over current revenue and regulatory timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The deal broadens Cemtrex’s capabilities in high-reliability electronics, flight instrumentation, and advanced system design.</li><li>Cemtrex acquired 100% of Invocon’s outstanding shares for $7.06 million, according to an earlier press release.</li><li>Invocon’s technologies have been used for 17 space shuttle systems and 10 international space station systems, among others.</li></ul>Shares of Cemtrex Inc. (CETX) jumped nearly 30% in premarket trading on Friday after the company formally launched its Aerospace &amp; Defense segment following the acquisition of Invocon, a Texas-based aerospace and defense engineering firm.According to a press release in November last year, Cemtrex acquired 100% of Invocon’s outstanding shares for $7.06 million.Cemtrex said near-term priorities include maintaining customer continuity, expanding proposal activity across missile defense and aerospace programs, and evaluating additional strategic opportunities.<h2 class="st-heading-2">Acquisition Rationale</h2>The acquisition expands Cemtrex’s capabilities in high-reliability electronics, flight instrumentation, wireless data acquisition, and complex system design.Invocon brings nearly four decades of experience developing advanced instrumentation, wireless sensing, and telemetry systems for satellites, launch vehicles, missiles, and space-based platforms. Its technologies have supported major government programs, including 17 space shuttle systems and 10 international space station systems, and have flown on more than 40 shuttle missions and over 30 target missile flights.The company also maintains long-standing relationships with the Missile Defense Agency and has a strong intellectual property portfolio covering hypervelocity impact detection, advanced sensing, and flight-system telemetry.Last month, Invocon secured awards under the Missile Defense Agency’s SHIELD IDIQ contract, a multi-award program with a total ceiling of up to $151 billion.“With the acquisition closed, we are focused on expanding Invocon’s participation across missile defense modernization, prime contractor programs, and space systems where reliability and execution determine outcomes. SHIELD strengthens our access to programs designed specifically to move faster, deploy new capabilities more rapidly, and deliver layered defense solutions at scale,” said Saagar Govil, Cemtrex Chairman and CEO.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CETX">CETX</a> on Stocktwits flipped to ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/CETX_png_28e815281c.webp" alt="CETX.png" width="922" height="97"><figcaption>CETX Sentiment Meter and Message Volumes at Premarket on Jan. 9, 2026 | Source: Stocktwits</figcaption></figure>One bullish user expects the stock price to climb up to $8-10 following the acquisition. It is currently trading at $3.7.<stembedurl>https://stocktwits.com/SouthMadeMack/message/641308617</stembedurl>Another user highlighted a potential technical indicator.<stembedurl>https://stocktwits.com/Crazzywt/message/641308447</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/balaji-srinivasan-backs-zcash-developers-after-team-exits-launches-new-wallet/cmU2aRwR4dE">Balaji Srinivasan Backs Zcash Developers After Team Exits And Launches New Wallet - ZEC Price Gains</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did CETX Stock Surge 30% In Pre-market Today?

Cemtrex has completed its acquisition of Texas-based engineering firm Invocon, establishing a new Aerospace & Defense segment.

Equity

5 ETFs to Buy for January 

5 ETFs to buy in January: momentum, small caps, chips, defense and healthcare shine as markets rally early in 2026 -- IWM, MTUM, SMH, XAR and IHE.

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>Daniel Jester of BMO Capital downgraded the stock to ‘Market Perform’ from ‘Outperform’, citing the low likelihood of a competing offer emerging.</li><li>Wolfe Research said the shares now offer little remaining upside.</li><li>Morgan Stanley also downgraded the stock to ‘Equal Weight’ and described Hg Capital’s proposal as reasonable.</li></ul>OneStream Inc. (OS) drew a wave of analyst downgrades following its agreement to be taken private by Hg Capital in an all-cash deal that values the financial software company at about $6.4 billion.&nbsp;Several Wall Street firms moved quickly to reset expectations, citing limited upside now that the stock trades close to the proposed buyout price.<h2 class="st-heading-2">Multiple Firms Reassess Valuation</h2>Daniel Jester of BMO Capital downgraded the stock to ‘Market Perform’ from ‘Outperform’ and trimmed his price target to $24 per share from $25, according to TheFly. The analyst said the downgrade reflects the agreed acquisition price and the low likelihood of a competing offer emerging.&nbsp;Wolfe Research echoed that view, cutting OneStream to ‘Peer Perform’ from ‘Outperform.’ The firm said the shares now offer little remaining upside since they trade near the deal price.Morgan Stanley also downgraded the stock to ‘Equal Weight’ from ‘Overweight’ while cutting its price target to $24 from $27. The firm described Hg Capital’s proposal as reasonable and said it expects the transaction to clear regulatory hurdles.&nbsp;The firm highlighted BlackLine Inc. (BL) as a potential beneficiary of the transaction, suggesting the buyout may be positive for comparable software assets.&nbsp;<a href="https://stocktwits.com/symbol/OS">OneStream stock</a> inched 0.1% lower in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hour.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_07_052407_png_a622e2f9c9.webp" alt="OS’s Sentiment Meter and Message Volume as of 05:20 a.m. ET on Jan. 7, 2026 | Source: Stocktwits" width="931" height="109"><figcaption>OS’s Sentiment Meter and Message Volume as of 05:20 a.m. ET on Jan. 7, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Mizuho Questions Chances Of A Bidding War</h2>Mizuho analyst Siti Panigrahi downgraded OneStream to ‘Neutral’ from ‘Outperform’ and trimmed the firm’s price target to $24. The firm said it does not expect a higher bid, noting that the agreed valuation aligns with recent software take-private transactions.&nbsp;OneStream’s acquisition agreement will take the company off public markets, reshaping its ownership structure. Under the terms of the deal, holders of OneStream stock will receive $24.00 per share in cash for their positions, a 31% premium to the stock’s closing price on January 5.&nbsp;Hg will become the majority voting stakeholder, and OneStream is expected to benefit from expanded resources to accelerate its artificial intelligence-driven offerings for corporate finance teams.&nbsp;OS stock has declined by over 13% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bmnr-tom-lee-bitcoin-never-topped-during-manufacturing-contraction/cmxyHoIR4cn">BMNR’s Tom Lee Agrees Bitcoin Has Never Topped During Manufacturing Contraction</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange.

OneStream Stock Faces Wave Of Analyst Downgrades As Hg Capital Deal Caps Upside

Several Wall Street firms moved quickly to reset expectations, citing limited upside now that the stock trades close to the proposed buyout price.

<ul class="summary-bullets"><li>Critical Metals is also in the spotlight after President Donald Trump renewed his calls for the U.S. to take control of Greenland.</li><li>Critical Metals’ recent joint venture with a Romanian state-owned company gives it long-term rights to 50% of Tanbreez output and raises the company’s total Tanbreez offtake to 75%.</li><li>An earlier Reuters report said that Trump administration officials were considering a stake in Critical Metals.</li></ul>Shares of Critical Metals Corp. (CRML) rallied over 23% on Tuesday after jumping over 251% in the past six months as speculations rose around the company’s strategic Greenland Tanbreez rare earth asset.Despite the stock’s steep rally in the last half a year, retail investors are still firmly bullish on the stock.The stock is also in the spotlight after President Donald Trump renewed his calls for the U.S. to take control of Greenland, shortly after the arrest of Venezuelan President Nicolas Maduro.<h2 class="st-heading-2">Rare Earths Interest</h2>Tanbreez in Greenland is among the largest known rare-earth deposits in the world, with some estimates suggesting that it contains over 27% of heavy rare-earth elements. The site also provides an important supply chain advantage because of its direct shipping access to the North Atlantic Ocean.Critical Metals acquired Greenland’s Tanbreez rare earth in mid 2024 for $5 million in cash and $211 million in stock.Recently, a Reuters report alleged that Critical Metals is expected to finalize its rare earths project in Greenland by the first quarter of 2026 wherein the remaining 25% of off-take agreements for its rare earths Tanbreez project in south Greenland will be completed. The company has already completed the sale of 75% of the planned output to the U.S. and Europe, as per the report.An earlier Reuters <a href="https://stocktwits.com/news-articles/markets/equity/critical-metals-anticipates-closing-rare-earths-supply-deal-in-greenland-by-2026-report/cL7BQ0iRECJ">report</a> also said that the Trump administration officials were considering a stake in Critical Metals.Critical Metals’ recent joint venture with a Romanian state-owned company gives it long-term rights to 50% of Tanbreez output and raises the company’s total Tanbreez offtake to 75%.Last month, Trump said that Greenland was an important part of U.S. national security. The country has a rich rare earths deposit. The U.S. is seeking to reduce its reliance on China for critical minerals as the Trump administration steps up efforts to strengthen domestic supply chains.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CRML stock jumped to ‘extremely bullish’ from ‘bullish’ territory over the past 24 hours amid ‘high’ message volume.One bullish user said that the Greenland situation was far bigger than Trump and the recent deals with Romania and the U.S. are positive.<stembedurl>https://stocktwits.com/Crypto_Jim/message/640990291</stembedurl>&nbsp;Another user highlighted the China risk and said rare earth stocks like CRML could surge to 100%.<stembedurl>https://stocktwits.com/fitoto/message/640990773</stembedurl>&nbsp;<a href="https://stocktwits.com/symbol/CRML">Shares of CRML </a>were among the top trending tickers on Stocktwits. The stock is up over 78% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

 Rare-earth mine in Baiyun'ebo or Bayan Obo. Baiyun'ebo or Bayan Obo is a mining town in Inner Mongolia in China.

CRML Shares In Spotlight After Surging Over 251% In Six Months — Why Is Retail Still Bullish?

Retail investors are optimistic around the company’s strategic Greenland Tanbreez rare earth asset. 

Bet on These 3 Small-Cap ETFs to Ride the January Effect

Small caps jump early in 2026, reviving the January Effect. ETFs like VTWO offer diversified exposure to potential seasonal and macro-driven gains.  

<ul class="summary-bullets"><li>The rare earths company has already completed the sale of 75% of the planned output to the U.S. and Europe, CEO Tony Sage said.&nbsp;</li><li>Critical Metals would also be open to investments from Washington, CEO Sage told Reuters.&nbsp;</li><li>The company is seeking a diversified supply to limit geopolitical risk.</li></ul>Critical Metals Corp. (CRML) is reportedly expected to finalize its rare earths project in Greenland by the first quarter of 2026.The company’s chief executive officer, Tony Sage, told Reuters that the remaining 25% of off-take agreements for its rare earths Tanbreez project in south Greenland is likely to be completed early next year, and the company would be open to an investment from Washington. As per an earlier Reuters report, Trump administration officials were <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/trump-administration-eyes-stake-company-developing-greenland-rare-earths-mine-2025-10-03/">considering</a> a stake in Critical Metals.Critical Metals has already completed the sale of 75% of the planned output to the U.S. and Europe, according to the report. The company is looking to keep its supply diversified to limit geopolitical risk, Sage said.<a href="https://stocktwits.com/symbol/CRML">Shares of CRML</a> climbed 0.14% on Wednesday morning at the time of writing.<h2 class="st-heading-2">Rare Earths Interest</h2>Growing interest from the Middle East indicates that energy-rich states are making efforts to build rare-earth processing capacity, Sage told Reuters. This includes potential processing partners in Saudi Arabia, Qatar, Bahrain, Oman, and the U.A.E., as well as the lower power costs and faster permitting than in the U.S. and Europe.The U.S. is aiming to reduce its reliance on China for critical minerals, which is currently the leader in the space. The Trump administration is stepping up efforts to strengthen domestic supply chains for critical minerals amid escalating trade tensions with the Asian country.Earlier this month, President Donald Trump touted Greenland as an important part of U.S. national security, adding that he had appointed a special envoy to the island to lead the charge.<h2 class="st-heading-2">Tanbreez Deposit</h2>Tanbreez in Greenland is among the largest known rare-earth deposits in the world, with some estimates suggesting that it contains over 27% of heavy rare-earth elements. The site also provides an important supply chain advantage because of its direct shipping access to the North Atlantic Ocean.Critical Metals’ recent joint venture with a Romanian state-owned company gives it long-term rights to 50% of Tanbreez output and raises the company’s total Tanbreez offtake to 75%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CRML shares trended in the ‘bearish’ territory over the past day amid ‘low’ message levels.<figure class="image"><img style="aspect-ratio:1281/160;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_31_at_9_59_25_PM_png_773cd7a9c7.webp" alt="On Stocktwits, retail sentiment around CRML shares trended in the ‘bearish’ territory over the past day amid ‘low’ message levels." width="1281" height="160"></figure>Shares of CRML have gained over 5% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Drag-line excavator mines rare earth materials. (Photo by Kostiantyn Liberov/Libkos/Getty Images)

Critical Metals Anticipates Closing Rare Earths Supply Deal In Greenland By Q1 2026: Report 

Critical Metals expects the remaining 25% of offtake agreements for its rare earths project in south Greenland to be completed early next year, as per the company’s CEO. 

Critical Metals Anticipates Closing Rare Earths Supply Deal In Greenland By Q1 2026: Report

<ul class="summary-bullets"><li>Innodata&nbsp;stock has mainly traded sideways in 2025 and remains well supported technically.</li><li>It is still up about 32% year to date despite missing the broader AI rally.</li><li>Retail engagement has surged on Stocktwits, while all analysts covering the stock have bullish recommendations.</li></ul>Small-cap Innodata Inc. (INOD) has come onto the radar of retail traders as the stock slowly recovers from the steep pullback following its early-October peak. Notwithstanding the volatility seen in the second half of the year,&nbsp;<a href="https://stocktwits.com/symbol/INOD">Innodata’s stock</a> is still up about 32%. The gains, however, are underwhelming relative to some artificial intelligence (AI) plays.Innodata has an AI connection, though in a more peripheral sense. The company functions as an AI enabler, providing data engineering services to a range of technology clients, including hyperscalers, financial services firms, and government agencies, and can rightly be called a "picks-and-shovels" play, a term used to refer to supplying essential tools and infrastructure to a booming industry.Based in New Jersey, Innodata offers a broad suite of capabilities, including data collection and annotation, data curation and enrichment, generative AI and large language model (LLM) support, AI model testing and validation, and content engineering and transformation.<h2 class="st-heading-2">Retail Interest Builds</h2>Innodata has drawn the attention of retail traders due to its credentials as an AI play. The one-year change in the follower count for the stock on Stocktwits is 141%. The message volume change on the stream over 30 days increased by about 550%.Retail sentiment toward the stock was ‘bullish’ as of early Tuesday, although the mood has seen volatility throughout the year.<figure class="image"><img style="aspect-ratio:719/439;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_30_at_7_08_33_AM_png_2f22f8b2a0.webp" alt="Screenshot 2025-12-30 at 7.08.33 AM.png" width="719" height="439"></figure>&nbsp;Retail chatter <a href="https://stocktwits.com/AI_Bull_/message/640382964">surrounded</a> a strategically significant “new relationship” that the company flagged on the third-quarter earnings call. Since the company stated that the unnamed partner is a leader in the military and government sectors, retail watchers played a guessing game, throwing up names such as Lockheed Martin and Palantir.Another watcher <a href="https://stocktwits.com/Stocks1234567891011/message/640369151">said</a> the Innodata story is only beginning.&nbsp;According to Koyfin, the average analyst price target for Innodata is $93.75, implying roughly 80% upside from current levels. All four analysts covering the stock have either a ‘Buy’ or ‘Strong Buy’ rating.In an October note, Wedbush analyst Daniel Ives named Innodata as among the top candidates that are likely to be acquired this year.&nbsp;<h2 class="st-heading-2">How INOD Stock Performed This Year</h2>Innodata did not partake substantially in the strong AI rally seen on either side of the across-the-board April tariff sell-off. The year’s move can be characterized as broadly sideways, interspersed with small rallies and pullbacks. Following the release of Innodata’s second-quarter results in late July, the stock picked up some upward momentum. The uptrend lasted for a month, until early October, when the stock began to retrace the move.&nbsp;&nbsp;The stock is currently well-supported by its 200-day simple moving average (SMA) ($51.30) on a one-year chart. The 14-day relative strength index (RSI) is currently at 42, suggesting the stock is approaching the neutral zone.<img src="https://news.stocktwits-cdn.com/INOD_YTD_Stock_Trajectory_png_01a69319c8.webp" alt="INOD YTD Stock Trajectory.png">Source: Koyfin<h2 class="st-heading-2">How Innodata’s Fundamentals Stack Up</h2>Innodata’s third-quarter results, released in early November, showed 20% year-over-year (YoY) growth in revenue to $62.6 million, and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) more than doubled to $42.2 million. The net income was at $8.3 million.&nbsp;Looking ahead, the company reiterated its guidance for 45% or more YoY organic growth for 2025, and hinted at “continued transformative growth in 2026 based on new wins and strong momentum."Last month, the company launched Innodata Federal, a dedicated government-focused business unit designed to deliver mission-critical AI solutions to U.S. defense, intelligence, and civilian agencies.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-ev-business-feels-heat-what-automotive-delivered-in-2025/cL74yLcREUi">Tesla’s Core EV Business Is Feeling The Heat — What Its Automotive Segment Really Delivered In 2025</a>

In this photo illustration, the Innodata logo is seen displayed on a smartphone and in the background. 

Innodata Emerges As Picks-And-Shovels AI Play Poised For 80% Upside Ahead – And It Is Back On Retail's Radar

Innodata operates as an AI enabler rather than a core AI platform, but is delivering strong revenue and EBITDA growth and guiding for 45%+ organic growth in 2025.

Innodata Emerges As Picks-And-Shovels AI Play Poised For 80% Upside Ahead – And It Is Back On Retail’s Radar

Innodata operates as an AI enabler rather than a core AI platform, but is delivering strong revenue and EBITDA growth and guiding for 45%+ organic growth in 2025.


<ul class="summary-bullets"><li>Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio.</li><li>The firm will use the proceeds from the sale of Pocono Pharma to continue developing AVERSA Fentanyl.</li><li>It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.</li></ul>Shares of Nutriband Inc. (<a href="https://stocktwits.com/symbol/NTRB">NTRB</a>) surged more than 18% on Monday after the company announced an agreement to sell 90% stake in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million.Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio following the acquisition, it stated.Nutriband will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl. The company develops transdermal drug delivery systems that are focused on preventing abuse and misuse of medications like opioids using its proprietary AVERSA Technology.<h2 class="st-heading-2">Bet On Abuse-Deterrent Aversa Fentanyl</h2>The U.S. government has been cracking down on illicit fentanyl. U.S. President Donald Trump earlier this month signed an executive order designating it as a weapon of mass destruction and recognizing the substance as a direct threat to U.S. national security.Nutriband’s AVERSA Fentanyl uses its abuse-deterrent technology, which is designed to improve the safety profile of transdermal drugs that are susceptible to abuse, such as fentanyl, while making sure these drugs remain accessible to patients who need them.Nutriband has been partnering with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.Nutriband had signed a non-binding Letter of Intent (LOI) with Qvanta Group of Companies to explore potential collaboration areas, including secure AI and analytics platforms for regulated pharmaceutical data, and cybersecurity that support abuse-deterrent technologies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:639/68;" src="https://news.stocktwits-cdn.com/ntrb_PNG_d487765902.webp" alt="Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes. " width="639" height="68"></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

What’s Driving Nutriband Shares Higher Today?

Nutriband has agreed to sell 90% of its stake in its subsidiary Pocono Pharmaceuticals for $5 million. 

Will the Ongoing Market Rally Continue in 2026? ETFs in Focus

S&P 500 momentum and retail inflows set the stage for a potential 2026 rally, with ETFs offering ways to ride the bullish trend.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF